Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) showed excellent renoprotective effects; however, the underlying mechanism remains not fully understood. Previous studies have revealed the importance of ferroptosis, which is closely related to oxidative stress, in the progression of DKD. In the current study, we hypothesized that SGLT2i could relieve ferroptosis and thereby alleviate renal injury in DKD due to their antioxidative stress effects.
Results:
Typical changes of ferroptosis including massive lipid peroxidation, compromised antioxidant capability, and iron overload were found in db/db mice and high glucose/high fat (HG/HF)-treated HK-2 cells. Furthermore, increased expression of hypoxia inducible factor 1α (HIF1α) and heme oxygenase 1 (HO1) was observed in db/db mice and HG/HF-treated HK-2 cells as well. Dapagliflozin treatment significantly ameliorated the ferroptosis-related changes via attenuating overactivation of the HIF1α/HO1 axis in vivo and in vitro. Besides, downregulation of the HIF1α/HO1 axis alleviated ferroptosis, while overexpression of HIF1α and HO1 aggravated ferroptosis induced by HG/HF in HK-2 cells.
Innovation and Conclusion:
This study revealed that SGLT2i played a renoprotective role in DKD, at least in part, through alleviating HIF1α/HO1-mediated ferroptosis. Antioxid. Redox Signal. 40, 492–509.
Get full access to this article
View all access options for this article.
References
1.
AbrahamNG, CaoJ, SacerdotiD, et al.Heme oxygenase: The key to renal function regulation. Am J Physiol Renal Physiol, 2009; 297(5):F1137–F1152; doi: 10.1152/ajprenal.90449.2008
2.
AdedoyinO, BodduR, TraylorA, et al.Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells. Am J Physiol Renal Physiol, 2018; 314(5):F702-f714; doi: 10.1152/ajprenal.00044.2017
3.
AlicicRZ, RooneyMT, TuttleKR. Diabetic kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol, 2017; 12(12):2032–2045; doi: 10.2215/cjn.11491116
AndersS, PylPT, HuberW. HTSeq—A Python framework to work with high-throughput sequencing data. Bioinformatics, 2015; 31(2):166–169; doi: 10.1093/bioinformatics/btu638
6.
AntarSA, AbdoW, TahaRS, et al.Telmisartan attenuates diabetic nephropathy by mitigating oxidative stress and inflammation, and upregulating Nrf2/HO-1 signaling in diabetic rats. Life Sci, 2021; 291:120260; doi: 10.1016/j.lfs.2021.120260
7.
BeckKF, PfeilschifterJ. Gasotransmitter synthesis and signalling in the renal glomerulus. Implications for glomerular diseases. Cell Signal, 2021; 77:109823; doi: 10.1016/j.cellsig.2020.109823
8.
BolgerAM, LohseM, UsadelB. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics, 2014; 30(15):2114–2120; doi: 10.1093/bioinformatics/btu170
9.
CaiT, KeQ, FangY, et al.Sodium-glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice. Cell Death Dis, 2020; 11(5):390; doi: 10.1038/s41419-020-2544-7
10.
ChangDY, LiXQ, ChenM, et al.Dapagliflozin ameliorates diabetic kidney disease via upregulating crry and alleviating complement over-activation in db/db mice. Front Pharmacol, 2021; 12:729334; doi: 10.3389/fphar.2021.729334
11.
ChangLC, ChiangSK, ChenSE, et al.Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis. Cancer Lett, 2018; 416:124–137; doi: 10.1016/j.canlet.2017.12.025
12.
ChenL, MeiG, JiangC, et al.Carbon monoxide alleviates senescence in diabetic nephropathy by improving autophagy. Cell Prolif, 2021; 54(6):e13052; doi: 10.1111/cpr.13052
13.
DarHH, TyurinaYY, Mikulska-RuminskaK, et al.Pseudomonas aeruginosa utilizes host polyunsaturated phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium. J Clin Invest, 2018; 128(10):4639–4653; doi: 10.1172/jci99490
14.
DawnB, BolliR. HO-1 induction by HIF-1: A new mechanism for delayed cardioprotection?. Am J Physiol Heart Circ Physiol, 2005; 289(2):H522–H524; doi: 10.1152/ajpheart.00274.2005
15.
DekkersCCJ, PetrykivS, LavermanGD, et al.Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab, 2018; 20(8):1988–1993; doi: 10.1111/dom.13301
16.
DixonSJ, LembergKM, LamprechtMR, et al.Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell, 2012; 149(5):1060–1072; doi: 10.1016/j.cell.2012.03.042
17.
DixonSJ, PatelDN, WelschM, et al.Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife, 2014; 3:e02523; doi: 10.7554/eLife.02523
18.
DongH, QiangZ, ChaiD, et al.Nrf2 inhibits ferroptosis and protects against acute lung injury due to intestinal ischemia reperfusion via regulating SLC7A11 and HO-1. Aging (Albany NY), 2020; 12(13):12943–12959; doi: 10.18632/aging.103378
19.
FengX, WangS, SunZ, et al.Ferroptosis enhanced diabetic renal tubular injury via HIF-1α/HO-1 pathway in db/db mice. Front Endocrinol, 2021; 12:626390; doi: 10.3389/fendo.2021.626390
20.
Friederich-PerssonM, ThörnE, HansellP, et al.Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress. Hypertension, 2013; 62(5):914–919; doi: 10.1161/hypertensionaha.113.01425
21.
Friedmann AngeliJP, SchneiderM, PronethB, et al.Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol, 2014; 16(12):1180–1191; doi: 10.1038/ncb3064
22.
GillardP, SchnellO, GroopP-H. The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes. Diabetes Res Clin Pract, 2020; 170:108462; doi: 10.1016/j.diabres.2020.108462
23.
HasegawaS, TanakaT, SaitoT, et al.The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease. Kidney Int, 2020; 97(5):934–950; doi: 10.1016/j.kint.2019.12.007
24.
HuJ, WangW, ZhangF, et al.Hypoxia inducible factor-1α mediates the profibrotic effect of albumin in renal tubular cells. Sci Rep, 2017; 7(1):15878; doi: 10.1038/s41598-017-15972-8
25.
JiangL, KonN, LiT, et al.Ferroptosis as a p53-mediated activity during tumour suppression. Nature, 2015; 520(7545):57–62; doi: 10.1038/nature14344
26.
JiangN, ZhaoH, HanY, et al.HIF-1α ameliorates tubular injury in diabetic nephropathy via HO-1-mediated control of mitochondrial dynamics. Cell Prolif, 2020; 53(11):e12909; doi: 10.1111/cpr.12909
27.
KaganVE, MaoG, QuF, et al.Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol, 2017; 13(1):81–90; doi: 10.1038/nchembio.2238
28.
KanehisaM, ArakiM, GotoS, et al.KEGG for linking genomes to life and the environment. Nucleic Acids Res, 2008; 36(Database Issue):D480–D484; doi: 10.1093/nar/gkm882
29.
KimD, LangmeadB, SalzbergSL. HISAT: A fast spliced aligner with low memory requirements. Nat Methods, 2015; 12(4):357–360; doi: 10.1038/nmeth.3317
LeeDW, AndersenJK. Role of HIF-1 in iron regulation: Potential therapeutic strategy for neurodegenerative disorders. Curr Mol Med, 2006; 6(8):883–893; doi: 10.2174/156652406779010849
32.
LeePJ, JiangBH, ChinBY, et al.Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem, 1997; 272(9):5375–5381.
33.
LiJ, LiuH, TakagiS, et al.Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules. JCI Insight, 2020; 5(6):e129034; doi: 10.1172/jci.insight.129034
34.
LiS, ZhengL, ZhangJ, et al.Inhibition of ferroptosis by up-regulating Nrf2 delayed the progression of diabetic nephropathy. Free Radic Biol Med, 2021; 162:435–449; doi: 10.1016/j.freeradbiomed.2020.10.323
35.
LinYC, ChangYH, YangSY, et al.Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc, 2018; 117(8):662–675; doi: 10.1016/j.jfma.2018.02.007
36.
LiuH, SridharVS, BouletJ, et al.Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: From biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism, 2021; 126:154918; doi: 10.1016/j.metabol.2021.154918
37.
LiuZZ, BullenA, LiY, et al.Renal oxygenation in the pathophysiology of chronic kidney disease. Front Physiol, 2017; 8:385; doi: 10.3389/fphys.2017.00385
38.
LokCN, PonkaP. Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem, 1999; 274(34):24147–24152; doi: 10.1074/jbc.274.34.24147
39.
MaH, WangX, ZhangW, et al.Melatonin suppresses ferroptosis induced by high glucose via activation of the Nrf2/HO-1 signaling pathway in type 2 diabetic osteoporosis. Oxid Med Cell Longev, 2020; 2020:9067610; doi: 10.1155/2020/9067610
40.
MiessH, DankworthB, GouwAM, et al.The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. Oncogene, 2018; 37(40):5435–5450; doi: 10.1038/s41388-018-0315-z
41.
NayakBK, ShanmugasundaramK, FriedrichsWE, et al.HIF-1 mediates renal fibrosis in OVE26 type 1 diabetic mice. Diabetes, 2016; 65(5):1387–1397; doi: 10.2337/db15-0519
42.
NespouxJ, VallonV. Renal effects of SGLT2 inhibitors: An update. Curr Opin Nephrol Hypertens, 2020; 29(2):190–198; doi: 10.1097/mnh.0000000000000584
43.
NeuenBL, YoungT, HeerspinkHJL, et al.SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol, 2019; 7(11):845–854; doi: 10.1016/s2213-8587(19)30256-6
44.
NikolicI, SaksidaT, ManganoK, et al.Pharmacological application of carbon monoxide ameliorates islet-directed autoimmunity in mice via anti-inflammatory and anti-apoptotic effects. Diabetologia, 2014; 57(5):980–990; doi: 10.1007/s00125-014-3170-7
45.
OtterbeinLE, ChoiAM. Heme oxygenase: colors of defense against cellular stress. Am J Physiol Lung Cell Mol Physiol, 2000; 279(6):L1029–L1037; doi: 10.1152/ajplung.2000.279.6.L1029
46.
PackerM. Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: Modulation by SGLT2 inhibitors and hypoxia mimetics. Am J Kidney Dis, 2021; 77(2):280–286; doi: 10.1053/j.ajkd.2020.04.016
47.
Papadopoulou-MarketouN, ChrousosGP, Kanaka-GantenbeinC. Diabetic nephropathy in type 1 diabetes: A review of early natural history, pathogenesis, and diagnosis. Diabetes Metab Res Rev, 2017; 33(2):2841; doi: 10.1002/dmrr.2841
48.
PerkovicV, JardineMJ, NealB, et al.Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med, 2019; 380(24):2295–2306; doi: 10.1056/NEJMoa1811744
49.
RavindranS, MunusamyS. Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease. J Cell Physiol, 2022; 237(2):1182–1205; doi: 10.1002/jcp.30621
50.
RobertsA, TrapnellC, DonagheyJ, et al.Improving RNA-Seq expression estimates by correcting for fragment bias. Genome Biol, 2011; 12(3):R22; doi: 10.1186/gb-2011-12-3-r22
51.
SeibtTM, PronethB, ConradM. Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic Biol Med, 2019; 133:144–152; doi: 10.1016/j.freeradbiomed.2018.09.014
52.
SeilerA, SchneiderM, FörsterH, et al.Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab, 2008; 8(3):237–248; doi: 10.1016/j.cmet.2008.07.005
53.
ShinSJ, ChungS, KimSJ, et al.Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One, 2016; 11(11):e0165703; doi: 10.1371/journal.pone.0165703
54.
StockwellBR, Friedmann AngeliJP, BayirH, et al.Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell, 2017; 171(2):273–285; doi: 10.1016/j.cell.2017.09.021
55.
StockwellBR, JiangX, GuW. Emerging mechanisms and disease relevance of ferroptosis. Trends Cell Biol, 2020; 30(6):478–490; doi: 10.1016/j.tcb.2020.02.009
56.
SugaharaM, TanakaS, TanakaT, et al.Prolyl hydroxylase domain inhibitor protects against metabolic disorders and associated kidney disease in obese type 2 diabetic mice. J Am Soc Nephrol, 2020; 31(3):560–577; doi: 10.1681/asn.2019060582
57.
SunHK, LeeYM, HanKH, et al.Phosphodiesterase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidney. Korean J Intern Med, 2012; 27(2):163–170; doi: 10.3904/kjim.2012.27.2.163
58.
TaharaA, TakasuT, YokonoM, et al.Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice. J Pharmacol Sci, 2016; 131(3):198–208; doi: 10.1016/j.jphs.2016.06.004
59.
TangZ, JuY, DaiX, et al.HO-1-mediated ferroptosis as a target for protection against retinal pigment epithelium degeneration. Redox Biol, 2021; 43:101971; doi: 10.1016/j.redox.2021.101971
60.
TervaertTW, MooyaartAL, AmannK, et al.Pathologic classification of diabetic nephropathy. J Am Soc Nephrol, 2010; 21(4):556–563; doi: 10.1681/asn.2010010010
61.
TiwariS, NdisangJF. The heme oxygenase system and type-1 diabetes. Curr Pharm Des, 2014; 20(9):1328–1337; doi: 10.2174/13816128113199990552
62.
TrapnellC, WilliamsBA, PerteaG, et al.Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol, 2010; 28(5):511–515; doi: 10.1038/nbt.1621
WangY, BiR, QuanF, et al.Ferroptosis involves in renal tubular cell death in diabetic nephropathy. Eur J Pharmacol, 2020; 888:173574; doi: 10.1016/j.ejphar.2020.173574
65.
WannerC, InzucchiSE, LachinJM, et al.Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med, 2016; 375(4):323–334; doi: 10.1056/NEJMoa1515920
66.
WarrenAM, KnudsenST, CooperME. Diabetic nephropathy: An insight into molecular mechanisms and emerging therapies. Expert Opin Ther Targets, 2019; 23(7):579–591; doi: 10.1080/14728222.2019.1624721
67.
WeiR, CuiX, FengJ, et al.Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice. Metab Clin Exp, 2020; 111:154324; doi: 10.1016/j.metabol.2020.154324
68.
WenY, LiuY, HuangQ, et al.Moringa oleifera Lam. seed extract protects kidney function in rats with diabetic nephropathy by increasing GSK-3β activity and activating the Nrf2/HO-1 pathway. Phytomedicine, 2022; 95:153856; doi: 10.1016/j.phymed.2021.153856
69.
WuY, WangJ, ZhaoT, et al.Di-(2-ethylhexyl) phthalate exposure leads to ferroptosis via the HIF-1α/HO-1 signaling pathway in mouse testes. J Hazard Mater, 2022; 426:127807; doi: 10.1016/j.jhazmat.2021.127807
70.
YangM, ChenP, LiuJ, et al.Clockophagy is a novel selective autophagy process favoring ferroptosis. Sci Adv, 2019; 5(7):eaaw2238; doi: 10.1126/sciadv.aaw2238
71.
YangWS, KimKJ, GaschlerMM, et al.Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A, 2016; 113(34):E4966–E4975; doi: 10.1073/pnas.1603244113
72.
YangWS, SriRamaratnamR, WelschME, et al.Regulation of ferroptotic cancer cell death by GPX4. Cell, 2014; 156(1–2):317–331; doi: 10.1016/j.cell.2013.12.010
73.
YaribeygiH, Simental-MendíaLE, BanachM, et al.The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update. Biomed Pharmacother, 2019; 120:109526; doi: 10.1016/j.biopha.2019.109526
74.
ZagerRA. Parenteral iron compounds: Potent oxidants but mainstays of anemia management in chronic renal disease. Clin J Am Soc Nephrol, 2006; 1(Suppl 1):S24–S31; doi: 10.2215/cjn.01410406
75.
ZhangX, GuanT, YangB, et al.SLC30A7 has anti-oxidant stress effects in high glucose-induced apoptosis via the NFE2L2/HMOX1 signal transduction pathway. Diabetes Res Clin Pract, 2021; 172:108445; doi: 10.1016/j.diabres.2020.108445
76.
ZhengJ, ConradM. The metabolic underpinnings of ferroptosis. Cell Metab, 2020; 32(6):920–937; doi: 10.1016/j.cmet.2020.10.011
77.
ZhouLT, ZhangZJ, CaoJY, et al.The unique molecular mechanism of diabetic nephropathy: A bioinformatics analysis of over 250 microarray datasets. Clin Kidney J, 2021; 14(6):1626–1638; doi: 10.1093/ckj/sfaa190
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
